HCQ/CQ and CAB combined treatment ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 74 | 下垂体性PRL分泌亢進症 | 1 |
74. 下垂体性PRL分泌亢進症
臨床試験数 : 19 / 薬物数 : 28 - (DrugBank : 10) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03400865 (ClinicalTrials.gov) | October 25, 2018 | 8/1/2018 | Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas | The Effect of Combined Treatment of Cabergoline With Hydroxychloroquine/Chloroquine for Resistant Prolactinomas | Resistance, Disease;Prolactinoma | Drug: HCQ/CQ and CAB combined treatment | Zhebao Wu | Xinqiao Hospital of Chongqing;First Hospital of China Medical University;Beijing Tiantan Hospital;First Affiliated Hospital of Wenzhou Medical University;First Affiliated Hospital of Fujian Medical University;Peking Union Medical College Hospital;Huashan Hospital;Chinese PLA General Hospital | Not yet recruiting | 18 Years | 70 Years | All | 30 | N/A | China |